Top Page
Defence Therapeutics
(OTC:DTC)
Defence Therapeutics (DTC) vs. S&P 500 (SPY)
Defence Therapeutics Business Overview & Revenue Model
Defence Therapeutics Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -71.19K | -90.92K | -13.82K | 0.00 | 0.00 | 0.00 | EBIT |
| -2.84M | -12.66M | -6.48M | ― | ― | -673.18K | EBITDA |
| -3.52M | -12.68M | -6.48M | 0.00 | -2.86M | -673.18K | Net Income Common Stockholders |
| -4.09M | -13.19M | -6.76M | -7.34M | -2.86M | -673.18K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 130.52K | 56.55K | 2.79M | 506.70K | 5.45M | 1.87M | Total Assets |
| 403.03K | 477.75K | 3.53M | 719.67K | 5.61M | 1.91M | Total Debt |
| 1.28M | 1.75M | 1.75M | 0.00 | 0.00 | 0.00 | Net Debt |
| 1.15M | 1.69M | -1.05M | -506.70K | -5.45M | -1.87M | Total Liabilities |
| 3.86M | 4.06M | 1.97M | 1.11M | 122.26K | 48.35K | Stockholders Equity |
| -3.45M | -3.58M | 1.57M | -387.56K | 5.49M | 1.86M |
| Cash Flow | Free Cash Flow | ||||
| -2.25M | -4.49M | -7.72M | -6.04M | -2.29M | -178.85K | Operating Cash Flow |
| -2.05M | -4.29M | -7.66M | -6.04M | -2.29M | -132.83K | Investing Cash Flow |
| -178.14K | -203.24K | -65.80K | 0.00 | 0.00 | -46.02K | Financing Cash Flow |
| 2.01M | 1.76M | 10.01M | 1.10M | 5.88M | 2.04M |
Defence Therapeutics Technical Analysis
Defence Therapeutics Peers Comparison
Defence Therapeutics Corporate Events
Defence Therapeutics Inc. has successfully closed the second tranche of its non-brokered private placement, raising $3.915 million through the issuance of units consisting of common shares and share purchase warrants. The proceeds will be utilized to advance the company’s preclinical and clinical programs and for general working capital. This financial boost is expected to enhance Defence’s capabilities in the biotechnology sector, supporting its ongoing development of next-generation radio-immuno-conjugate and ADC products.
Defence Therapeutics announced its participation in the Biotech Showcase during the J.P. Morgan Healthcare Conference in San Francisco, aiming to connect with industry leaders and potential partners. The company has closed the first tranche of its non-brokered private placement, raising $300,000 to fund preclinical and clinical programs, illustrating its strategic efforts to enhance its market presence and technological advancements.
Defence Therapeutics Inc. has strengthened its patent portfolio with key patent issuances and allowances across several jurisdictions, particularly enhancing its Accum® dimer and multimer technology. These developments are expected to provide Defence with market exclusivity until 2043 and validate its innovative approach, facilitating future licensing agreements and strategic partnerships to advance its anti-cancer therapeutics and vaccine technologies.
Defence Therapeutics Inc., a Canadian biopharmaceutical company, has announced a private placement of up to $4.2 million to support its preclinical and clinical programs. The offering consists of seven million units, each comprising a common share and a warrant, aimed at advancing the company’s innovative radiopharmaceutical and ADC products.
Defence Therapeutics Inc. announces the addition of molecular and antibody research expert Dr. Elias Theodorou to its board of directors, enhancing its scientific expertise. Dr. Theodorou, with over 25 years of experience, will provide guidance for Defence’s development, particularly in the USA. Additionally, the company appointed Mr. Arnab De as CFO and Corporate Secretary.